Axogen, Inc. AXGN

ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™. “This is a significant day for Axogen and the surgeons and pa

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.The strategic acquisition integrates NerveTape, the first FDA-approved sutureless nerve repair device, into Axogen’s existing surgical solutions for restoring peripheral nerve function.Funding The AcquisitionTo finance the $200 million purchase price, Axogen launched an underwritten public offering of 4.91 million shares of common stock, pri

Both AXGN and COO are seeing unusual options volume

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the public of $42.50 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets Axogen’s commercial infrastructure, surgeon relationships and hospital contracting are expected to accelerate adoption and expand access to NerveTape™ Transaction expected to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year following closing while Axogen remains free cash flow positive ALACHUA, Fl

ALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development and

In the second quarter of 2026, Axogen reported sales of US$69.73 million, a net loss of US$1.52 million, and lifted its full-year 2026 revenue outlook to at least US$279 million, implying revenue growth of at least 24%. A key highlight was the rapid expansion of Axogen’s breast reconstruction franchise, which drove more than half of quarterly revenue and reshaped the company’s product mix and margin profile. We’ll now explore how Axogen’s upgraded 2026 revenue outlook and breast...

Axogen Inc (AXGN) reports a robust 23% revenue increase, driven by the breast market, while navigating margin pressures and strategic expansion.

Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic investment from Axogen, Inc. (NASDAQ: AXGN), the global leader in surgical solutions for restoration of peripheral nerve function, as its technology continues to advance through clinical development. The investment is part of Trace's Series A financing round with additional investors expected to join.

Raises Full Year Revenue Guidance to at Least 24% Growth or $279 millionALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2026. Second Quarter Financial Results Revenue was $69.7 million, an increase of 23.1% compared with $56.7 million

NZS Capital, LLC, an investment management company, released its “NZS Growth Equity Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Equity markets delivered a strong performance in the second quarter of 2026, driven by demand for AI infrastructure, geopolitical stabilization, and positive earnings reports. The portfolio achieved a gross […]

NZS shifts capital toward AI infrastructure and healthcare leaders

Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026Andrew Macan to step down as Executive Vice President, Chief Legal Officer & Corporate Secretary, effective August 15, 2026 MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines